Recorded webinars
Insights into ATTR-CM Management: Expert Presentations from ESC HF Barcelona 2026
This page features two expert video presentations from ESC HF Barcelona 2026.
Dr. Peter-Paul Zwetsloot and Professor Marianna Fontana share key findings on transthyretin amyloid cardiomyopathy (ATTR-CM), including comparative data on acoramidis versus tafamidis and the role of outpatient worsening heart failure as a marker of disease progression.
Outpatient Worsening Heart Failure in ATTR Cardiomyopathy: Insights from the ATTRibute-CM Trial
Duration: 4:20 mins
Professor Fontana presents a post-hoc analysis of the ATTRibute-CM trial showing that outpatient worsening heart failure is an important marker of disease progression in ATTR cardiomyopathy. Nearly 47% of participants experienced worsening heart failure, which was linked to higher risks of death and cardiovascular hospitalisation. Acoramidis significantly reduced this risk and improved clinical outcomes, highlighting the value of early treatment in ATTR-CM.
Comparative Effectiveness of Acoramidis vs. Tafamidis in ATTR-CM
Duration: 5:20 mins
Dr. Peter-Paul Zwetsloot reviews the ReplicATTR study, which uses trial emulation and indirect treatment comparison to assess acoramidis versus tafamidis in ATTR-CM. Using US electronic medical record data, the study found a 22% relative reduction in all-cause mortality with acoramidis. He highlights the relevance of these findings for clinical decision-making, while noting the limitations of non-randomised analyses.
PP-PF-CAR-IE-0019-1 | June 2026